Bayer

(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease (COPD), known as NOTUS, has demonstrated promising results. The trial found that Dupixent reduced COPD exacerbations by 34% compared to … Read the full press release →

(IN BRIEF) German materials manufacturer Covestro has announced a global partnership with Chinese automotive trim company Xinquan Automotive during the China International Import Expo in Shanghai. This strategic alliance aims to strengthen Xinquan’s presence in North America, Europe, and ASEAN … Read the full press release →

(IN BRIEF) Bayer has invested $250 million in a new cell therapy production plant in Berkeley, California, USA. This investment aims to support the production of materials for clinical trials and potential commercial launches of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an … Read the full press release →

(IN BRIEF) Bayer is making a significant investment of EUR 220 million in research and development (R&D) at its Monheim site in Germany, focusing on its Crop Protection business. This represents the company’s largest single investment in Crop Protection in … Read the full press release →

(IN BRIEF) Pairwise and Bayer have entered into a new five-year, multi-million Dollar collaboration focusing on gene-edited short-stature corn. Building on their initial partnership for corn, soy, wheat, cotton, and canola, this collaboration aims to optimize and enhance gene-edited short-stature … Read the full press release →

(IN BRIEF) BlueRock Therapeutics and bit.bio have announced a collaboration and option agreement to discover and manufacture iPSC-derived regulatory T cells (Tregs) for therapeutic use. Tregs are crucial for immune system balance and controlling excessive immune reactions, making them potential … Read the full press release →

(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release →

(IN BRIEF) A scientific statement published in the European Journal of Preventive Cardiology highlights that childhood obesity is a critical factor leading to cardiovascular disease (CVD) in adulthood. Childhood obesity is on the rise globally, and the associated problems of … Read the full press release →

Not intended for U.S. and UK Media (IN BRIEF) Bayer AG has partnered with Acuitas Therapeutics, Inc. to enhance its gene therapy portfolio. Acuitas’ lipid nanoparticle (LNP) delivery technology will enable targeted and efficient delivery of gene editing RNA components … Read the full press release →

Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, … Read the full press release →